MedPath
FDA Approval

acamprosate calcium

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
November 6, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Acamprosate(333 mg in 1 1)

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

acamprosate calcium

Product Details

NDC Product Code
68382-569
Application Number
ANDA205995
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
November 6, 2023
Code: 59375N1D0UClass: ACTIBQuantity: 333 mg in 1 1
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61UClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
POLYETHYLENE GLYCOL 8000Inactive
Code: Q662QK8M3BClass: IACT
METHACRYLIC ACIDInactive
Code: 1CS02G8656Class: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
POVIDONE K90Inactive
Code: RDH86HJV5ZClass: IACT
SODIUM BICARBONATEInactive
Code: 8MDF5V39QOClass: IACT
TALCInactive
Code: 7SEV7J4R1UClass: IACT
SODIUM LAURYL SULFATEInactive
Code: 368GB5141JClass: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2Class: IACT
© Copyright 2025. All Rights Reserved by MedPath